- 2009 First Quarter Reported Diluted Earnings per Share were $0.89,
Consistent with the Prior Year, and Diluted Earnings per Share,
Excluding Certain Significant Items, Increased 1% to $0.95
- Worldwide Net Revenue Decreased 6% for the 2009 First Quarter and
Increased 2%, Excluding the Impact of Foreign Exchange
- First Quarter Net Revenue Growth, Excluding the Impact of Foreign
Exchange, was Driven by Increases of 23% for Enbrel (outside the
U.S. and Canada), 19% for Prevnar and 12% for Nutritionals
- Reaffirms Guidance of $3.33 to $3.53 for Full Year Diluted Earnings
per Share, Excluding Certain Significant Items
MADISON, N.J., April 29 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2009 first quarter ended March 31, 2009. Worldwide net revenue decreased 6% to $5.4 billion for the 2009 first quarter. Excluding the unfavorable impact of foreign exchange, worldwide net revenue increased 2% for the 2009 first quarter.
"Wyeth delivered a solid first quarter led by double-digit revenue growth in constant dollars from core product franchises Enbrel, outside the U.S. and Canada, Prevnar and Nutritionals," said Bernard Poussot, Chairman, President and Chief Executive Officer. "Enbrel and Prevnar are the top products in their categories as more patients around the world benefit from Wyeth's innovative medicines. We are committed to meeting our financial targets while working with Pfizer to shape the world's premier biopharmaceutical company."
Product Highlights for the 2009 First Quarter
The following table presents worldwide net revenue from Wyeth's principal products for the 2009 first quarter together wi
Copyright©2009 PR Newswire.
All rights reserved